Voronistat in Pediatric Patients With Drug Resistant Epilepsy
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The study evaluates the safety, tolerability, and efficacy of Vorinostat in addition to
standard of care anti-epileptic drugs in pediatric patients with medically refractory
epilepsy. All participants entering the treatment phase will receive Vorinostat.